微生物来源的抗结核药物国内外生产情况、研发状况及市场动态

由于结核病具有严重的危害性，人类从未停止过与其抗争。微生物来源的抗结核药物作为人类抵御结核病侵袭的重要武器之一，具有很多防治结核的优势。这类药物品种繁多，在临床中有广泛的应用。随着新的致病菌的出现以及结核杆菌耐药率的不断提高，多药耐药结核菌感染的诊治丽临很大的挑战。鉴于经济、政治、科技、文化环境的差异，不同时期和不同国家，其市场情况也有一定变化。本文对当前这类药物国内外生产情况、研发进展及市场动态进行分析研究，并提供相应建议，以期为相关企业制定营销战略决策起导向作用。

The Abroad and Home Production Situation,R & D Progress and Market Dynamics of Anti-tuberculosis Agents from Microorganisms

Because of the TB＇s damage was very terrible, so the humanity had never stopped fighting with it. The anti-TB drugs from microorganism as one of the most important weapons to resist the invasion of the TB, which possessed many advantages. The kinds of the anti-TB drugs were various, and these drugs had been used widely in the clinical. With the emergence of new pathogenic bacteria and continual increase of tuberculosis resistance rate, the improvement of diagnosis and treatment of MDR-tuberculosis infections were faced a great challenge. As the differences in the economy, politic, technology and culture, different countries at different times, their markets had certainly changed. The production situation, R ＆ D progress and market dynamics of anti-tuberculosis medicine from microorganisms were detail analysed. At the same time, a number of recommendations was given, It was expected that there will be some guide for the relevant enterprises and government departments to formulate business strategies.